These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 33575322)
1. The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy. Cao W; Li M; Zhang L; Lu Y; Wu S; Shen G; Chang M; Liu R; Gao Y; Hao H; Hu L; Yi W; Pan CQ; Xie Y Biomed Res Int; 2021; 2021():2178143. PubMed ID: 33575322 [TBL] [Abstract][Full Text] [Related]
2. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy. Cao W; Lu H; Zhang L; Wang S; Deng W; Jiang T; Lin Y; Yang L; Bi X; Lu Y; Zhang L; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Hu L; Xie Y; Li M Front Immunol; 2022; 13():1067362. PubMed ID: 36479104 [TBL] [Abstract][Full Text] [Related]
3. CD56 Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839 [TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir. Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117 [TBL] [Abstract][Full Text] [Related]
5. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB. Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467 [TBL] [Abstract][Full Text] [Related]
6. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. Micco L; Peppa D; Loggi E; Schurich A; Jefferson L; Cursaro C; Panno AM; Bernardi M; Brander C; Bihl F; Andreone P; Maini MK J Hepatol; 2013 Feb; 58(2):225-33. PubMed ID: 23046671 [TBL] [Abstract][Full Text] [Related]
7. Changes of natural killer cells' phenotype in patients with chronic hepatitis B in intermittent interferon therapy. Bi X; Xie S; Wu S; Cao W; Lin Y; Yang L; Jiang T; Deng W; Wang S; Liu R; Gao Y; Shen G; Chang M; Hao H; Xu M; Chen X; Hu L; Lu Y; Zhang L; Xie Y; Li M Front Immunol; 2023; 14():1116689. PubMed ID: 36793722 [TBL] [Abstract][Full Text] [Related]
8. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. Boglione L; Cariti G; Di Perri G; D'Avolio A J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932 [TBL] [Abstract][Full Text] [Related]
9. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860 [TBL] [Abstract][Full Text] [Related]
10. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir. Zhao PW; Jia FY; Shan YX; Ji HF; Feng JY; Niu JQ; Ayana DA; Jiang YF Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):190-6. PubMed ID: 23278368 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a]. Luo XD; Chen XP; Chen R; Chen XF; Huang J Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620 [TBL] [Abstract][Full Text] [Related]
12. Effect of Antiviral Therapy During Pregnancy on Natural Killer Cells in Pregnant Women With Chronic HBV Infection. Wang F; Xie S; Ran C; Hao H; Jiang T; Deng W; Bi X; Lin Y; Yang L; Sun F; Zeng Z; Xie Y; Li M; Yi W Front Immunol; 2022; 13():893628. PubMed ID: 35677040 [TBL] [Abstract][Full Text] [Related]
13. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Chen S; Zhou J; Wu X; Meng T; Wang B; Liu H; Wang T; Zhao X; Kong Y; Wu S; Ou X; Jia J; Sun Y; You H Hepatol Int; 2021 Jun; 15(3):611-620. PubMed ID: 33677771 [TBL] [Abstract][Full Text] [Related]
14. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216 [TBL] [Abstract][Full Text] [Related]
15. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion. Bruder Costa J; Dufeu-Duchesne T; Leroy V; Bertucci I; Bouvier-Alias M; Pouget N; Brevot-Lutton O; Bourliere M; Zoulim F; Plumas J; Aspord C; PLoS One; 2016; 11(6):e0158297. PubMed ID: 27348813 [TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir. Sonneveld MJ; Zoutendijk R; Hansen BE; Janssen HL Antivir Ther; 2012; 17(8):1605-8. PubMed ID: 22898565 [TBL] [Abstract][Full Text] [Related]
17. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. Xie Q; Zhou H; Bai X; Wu S; Chen JJ; Sheng J; Xie Y; Chen C; Chan HL; Zhao M Clin Infect Dis; 2014 Dec; 59(12):1714-23. PubMed ID: 25190434 [TBL] [Abstract][Full Text] [Related]
18. Functional restoration of CD56 Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033 [TBL] [Abstract][Full Text] [Related]
19. Treatment of pegylated interferon-α2a in chronic hepatitis B patients demonstrating a spontaneous decline in HBV DNA after acute exacerbation. Cai Q; Chen F; Shao X; Zhang X; Zhao Z; Gao Z Antivir Ther; 2015; 20(2):217-24. PubMed ID: 25138110 [TBL] [Abstract][Full Text] [Related]
20. Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Werner JM; Serti E; Chepa-Lotrea X; Stoltzfus J; Ahlenstiel G; Noureddin M; Feld JJ; Liang TJ; Rotman Y; Rehermann B Hepatology; 2014 Oct; 60(4):1160-9. PubMed ID: 24700342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]